Cargando…

Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer

Liquid biopsy has emerged as a promising non-invasive way to diagnose tumor and monitor its progression. Different types of liquid biopsies have different advantages and limitations. In the present research, we compared the use of two types of liquid biopsy, extracellular vesicle-derived DNA (EV-DNA...

Descripción completa

Detalles Bibliográficos
Autores principales: Thakur, Kavita, Singh, Manu Smriti, Feldstein-Davydova, Sara, Hannes, Victoria, Hershkovitz, Dov, Tsuriel, Shlomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393490/
https://www.ncbi.nlm.nih.gov/pubmed/34440345
http://dx.doi.org/10.3390/genes12081171
_version_ 1783743738268352512
author Thakur, Kavita
Singh, Manu Smriti
Feldstein-Davydova, Sara
Hannes, Victoria
Hershkovitz, Dov
Tsuriel, Shlomo
author_facet Thakur, Kavita
Singh, Manu Smriti
Feldstein-Davydova, Sara
Hannes, Victoria
Hershkovitz, Dov
Tsuriel, Shlomo
author_sort Thakur, Kavita
collection PubMed
description Liquid biopsy has emerged as a promising non-invasive way to diagnose tumor and monitor its progression. Different types of liquid biopsies have different advantages and limitations. In the present research, we compared the use of two types of liquid biopsy, extracellular vesicle-derived DNA (EV-DNA) and cell-free DNA (cfDNA) for identifying tumor mutations in patients with colon carcinoma. Method: DNA was extracted from the tumor tissue of 33 patients diagnosed with colon carcinoma. Targeted NGS panel, based on the hotspots panel, was used to identify tumor mutations. Pre-surgery serum and plasma were taken from the patients in which mutation was found in the tumor tissue. Extracellular vesicles were isolated from the serum followed by the extraction of EV-DNA. CfDNA was extracted from the plasma. The mutations found in the tumor were used to detect the circulating tumor DNA using ultra-deep sequencing. We compared the sensitivity of mutation detection and allele frequency obtained in EV-DNA and cfDNA. Results: The sensitivity of mutation detection in EV-DNA and cfDNA was 61.90% and 66.67%, respectively. We obtained almost identical sensitivity of mutation detection in EV-DNA and cfDNA in each of the four stages of colon carcinoma. The total DNA concentration and number mutant copies were higher in cfDNA vs. EV-DNA (p value = 0.002 and 0.003, respectively). Conclusion: Both cfDNA and EV-DNA can serve as tumor biomarkers. The use of EV-DNA did not lead to improved sensitivity or better detection of tumor DNA in the circulation.
format Online
Article
Text
id pubmed-8393490
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83934902021-08-28 Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer Thakur, Kavita Singh, Manu Smriti Feldstein-Davydova, Sara Hannes, Victoria Hershkovitz, Dov Tsuriel, Shlomo Genes (Basel) Article Liquid biopsy has emerged as a promising non-invasive way to diagnose tumor and monitor its progression. Different types of liquid biopsies have different advantages and limitations. In the present research, we compared the use of two types of liquid biopsy, extracellular vesicle-derived DNA (EV-DNA) and cell-free DNA (cfDNA) for identifying tumor mutations in patients with colon carcinoma. Method: DNA was extracted from the tumor tissue of 33 patients diagnosed with colon carcinoma. Targeted NGS panel, based on the hotspots panel, was used to identify tumor mutations. Pre-surgery serum and plasma were taken from the patients in which mutation was found in the tumor tissue. Extracellular vesicles were isolated from the serum followed by the extraction of EV-DNA. CfDNA was extracted from the plasma. The mutations found in the tumor were used to detect the circulating tumor DNA using ultra-deep sequencing. We compared the sensitivity of mutation detection and allele frequency obtained in EV-DNA and cfDNA. Results: The sensitivity of mutation detection in EV-DNA and cfDNA was 61.90% and 66.67%, respectively. We obtained almost identical sensitivity of mutation detection in EV-DNA and cfDNA in each of the four stages of colon carcinoma. The total DNA concentration and number mutant copies were higher in cfDNA vs. EV-DNA (p value = 0.002 and 0.003, respectively). Conclusion: Both cfDNA and EV-DNA can serve as tumor biomarkers. The use of EV-DNA did not lead to improved sensitivity or better detection of tumor DNA in the circulation. MDPI 2021-07-29 /pmc/articles/PMC8393490/ /pubmed/34440345 http://dx.doi.org/10.3390/genes12081171 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Thakur, Kavita
Singh, Manu Smriti
Feldstein-Davydova, Sara
Hannes, Victoria
Hershkovitz, Dov
Tsuriel, Shlomo
Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer
title Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer
title_full Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer
title_fullStr Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer
title_full_unstemmed Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer
title_short Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer
title_sort extracellular vesicle-derived dna vs. cfdna as a biomarker for the detection of colon cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393490/
https://www.ncbi.nlm.nih.gov/pubmed/34440345
http://dx.doi.org/10.3390/genes12081171
work_keys_str_mv AT thakurkavita extracellularvesiclederiveddnavscfdnaasabiomarkerforthedetectionofcoloncancer
AT singhmanusmriti extracellularvesiclederiveddnavscfdnaasabiomarkerforthedetectionofcoloncancer
AT feldsteindavydovasara extracellularvesiclederiveddnavscfdnaasabiomarkerforthedetectionofcoloncancer
AT hannesvictoria extracellularvesiclederiveddnavscfdnaasabiomarkerforthedetectionofcoloncancer
AT hershkovitzdov extracellularvesiclederiveddnavscfdnaasabiomarkerforthedetectionofcoloncancer
AT tsurielshlomo extracellularvesiclederiveddnavscfdnaasabiomarkerforthedetectionofcoloncancer